Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03293966
Other study ID # PRIMACIE
Secondary ID
Status Completed
Phase
First received
Last updated
Start date June 1, 2016
Est. completion date December 31, 2017

Study information

Verified date May 2018
Source Groupe Hospitalier Paris Saint Joseph
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The continuity of the medicinal care between the city and the hospital stays a major organizational stake and of safety of patients' therapeutic care.This takeover is more complex when it concerns pathology needed lots of hospitalization and included the intervention of multiple healthcare practionners. This is clearly the case of cancer coverage.

The optimization of the therapeutic suppor in town is based on pharmaceutical advice strengthening but also on the pharmaceutical analysis to check the entire treatments' prescription and eventual medicinal interactions which ensue from it.That's why it's important to have a medicinal conciliation that takes into account all the medecine taken or have to be taken by the patient.

A specific support was developped by nurses , doctors and pharmacist ; it's a care coordination card that can be put easely in a pocket by the patient.

The aim of the study is that this card can be also used as a communication tools by sharing the prescription done at the release of hospital by using an IT link (flea datamatrix) for the patients Via the use of an IT link (flea datamatrix) for the patients whose pathology is complex in term of extra hospital coverage.


Description:

The aim of this strudy is to evaluate with community pharmacists the impact of a new information system on the prevalence of dispensing difficulties reported by pharmacies when hospitalized patients leave the city. This information system will be based on the care coordination card implemented by a secure computer link allowing the use of information on treatments prescribed at the end of hospitalization. Patient management is not changed by this protocol. Only the information of the pharmacist, which is the object of the study, is increased.


Recruitment information / eligibility

Status Completed
Enrollment 47
Est. completion date December 31, 2017
Est. primary completion date February 28, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- all patient admitted in onco-thoracic service

- Handled by an anticancer agent

- Having frequented the same city pharmacy for at least 3 months

Exclusion Criteria:

- hospitalization above 21 days

- refusing participation

- palliative care

- misunderstanding of french language

- frequenting several pharmacy

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
France Groupe Hospitalier Paris Saint Joseph Paris Ile-de-France

Sponsors (1)

Lead Sponsor Collaborator
Groupe Hospitalier Paris Saint Joseph

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Composite criteria including all the dysfunctions noticed at the release of the hospital prescription intended to be dispensed in town. 7days+/- 2 days
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05217069 - FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC Phase 2
Active, not recruiting NCT05185388 - Socioeconomic Inequalities in the Diagnosis and Treatment of Colon and Ovarian Cancer in England Between 2016-2017
Withdrawn NCT04253249 - Pancreatic Cyst Ablation With a Monopolar Radiofrequency Ablation Probe
Recruiting NCT03377829 - A Multicenter Trial of PLA vs. Surgery for Treating PTMC N/A
Not yet recruiting NCT04034173 - Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation Phase 2